Circaea mollis Siebold & Zucc. Alleviates postmenopausal osteoporosis in a mouse model via the BMP-2/4/Runx2 pathway

被引:14
作者
Park, Ji Hye [1 ,2 ]
Son, Yang Ju [1 ]
Lee, Chang Ho [2 ]
Nho, Chu Won [1 ]
Yoo, Gyhye [1 ]
机构
[1] Korea Inst Sci & Technol KIST, Gangneung Inst Nat Prod, Smart Farm Res Ctr, Nat Prod Res Ctr, Kangnung 25451, Gangwon Do, South Korea
[2] Gangneung Wonju Natl Univ, Coll Biol, Kangnung 25457, South Korea
关键词
Circaea mollis Siebold & Zucc; Postmenopausal osteoporosis; Osteoblast differentiation; Runt-related transcription factor 2; Bone morphogenetic protein 2/4; ESTROGEN-RECEPTOR-ALPHA; DIFFERENTIATION; OSTEOBLAST; EXPRESSION; CELLS; OSTEOCLASTS; PREVENTION; MECHANISMS; INDUCTION;
D O I
10.1186/s12906-020-02914-7
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
Background: Circaea mollis Sieb. & Zucc. has been used as a traditional herbal medicine in Hani Ethnopharmacy and possesses anti-arthritic activities. This study aimed to investigate the effect of Circaea mollis Siebold & Zucc on postmenopausal osteoporosis. Methods: For in vitro study, MCF7 breast cancer cells and MC3T3-E1 pre-osteoblast cells were utilized to estimate estrogenic and osteogenic activity. Osteoblastic markers were measured by western blot and real-time PCR. For in vivo study, female mature C57BL/6 mice were ovariectomized and oral administrated with 10 mg/kg and 40 mg/kg of EECM respectively. Results: EtOH extract of Circaea mollis Siebold & Zucc. (EECM) increased alkaline phosphatase activity and osteoblast marker levels at day 7 during differentiation of mouse preosteoblasts. EECM reduced osteoclast differentiation and bone resorption in an osteoblast-osteoclast primary co-culture system. In ovariectomized mice, EECM prevented the decrease in bone mineral density and recovered OSX and Runx2 via BMP2/4, Smad1/5/9 and p38. Conclusions: The results suggest that EECM may be effective in preventing bone loss, offering a promising alternative for the nutritional management of postmenopausal osteoporosis.
引用
收藏
页数:11
相关论文
共 26 条
  • [1] Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor κB (RANK) receptors
    Arai, F
    Miyamoto, T
    Ohneda, O
    Inada, T
    Sudo, T
    Brasel, K
    Miyata, T
    Anderson, DM
    Suda, T
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 190 (12) : 1741 - 1754
  • [2] Phenotypic Characterization, Osteoblastic Differentiation, and Bone Regeneration Capacity of Human Embryonic Stem Cell-Derived Mesenchymal Stem Cells
    Arpornmaeklong, Premjit
    Brown, Shelley E.
    Wang, Zhuo
    Krebsbach, Paul H.
    [J]. STEM CELLS AND DEVELOPMENT, 2009, 18 (07) : 955 - 968
  • [3] The estrogenic effects of apigenin, phloretin and myricetin based on uterotrophic assay in immature Wistar albino rats
    Barlas, Nurhayat
    Ozer, Saadet
    Karabulut, Gozde
    [J]. TOXICOLOGY LETTERS, 2014, 226 (01) : 35 - 42
  • [4] Black DM, 2016, NEW ENGL J MED, V374, P2096, DOI 10.1056/NEJMc1602599
  • [5] Natural Products from Chinese Medicines with Potential Benefits to Bone Health
    Che, Chun-Tao
    Wong, Man Sau
    Lam, Christopher Wai Kei
    [J]. MOLECULES, 2016, 21 (03):
  • [6] Osteoblast as a target of anti-osteoporotic treatment
    Corrado, Addolorata
    Sanpaolo, Eliana Rita
    Di Bello, Silvana
    Cantatore, Francesco Paolo
    [J]. POSTGRADUATE MEDICINE, 2017, 129 (08) : 858 - 865
  • [7] Bone remodelling at a glance
    Crockett, Julie C.
    Rogers, Michael J.
    Coxon, Fraser P.
    Hocking, Lynne J.
    Helfrich, Miep H.
    [J]. JOURNAL OF CELL SCIENCE, 2011, 124 (07) : 991 - 998
  • [8] Bisphosphonates: Mechanism of action and role in clinical practice
    Drake, Mathew T.
    Clarke, Bart L.
    Khosla, Sundeep
    [J]. MAYO CLINIC PROCEEDINGS, 2008, 83 (09) : 1032 - 1045
  • [9] DUCY P, 1995, MOL CELL BIOL, V15, P1858
  • [10] Eastell R, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.69, 10.1038/nrdp.2016.70]